Roka Bioscience Reports Fourth Quarter and Full Year 2016 Financial Results

Conference Call

Roka Bioscience will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and answer questions. During the conference call, material information concerning the Company, its operations, strategies and prospects may be discussed.  To listen to the conference call live, go to http://rokabio.investorroom.com/ or dial 1-888-347-1331 for domestic callers and 1-412-902-4277 for international callers.  A replay of the conference call will be available after the completion of the call by dialing 1-877-344-7529 (domestic) and 1-412-317-0088 (international). The replay access code is 10102626. An online archive of the conference call will also be available at http://rokabio.investorroom.com.

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  For more information, visit http://rokabio.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the "Exchange Act"). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we "believe", "expect", "anticipate", "plan" and similar expressions) that are not statements of historical fact should be considered forward-looking statements and should be read in conjunction with the Condensed Financial Statements  included in this press release and the discussion below. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law.  Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Investor Contact:

Roka Bioscience, Inc.
ir@rokabio.com
855-ROKABIO (855-765-2246)

Condensed Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share data)
	Three Months Ended December 31,								Year Ended December 31,
	2016				2015				2016				2015
Revenue	$	1,906			$	1,501			$	7,242			$	5,985
Operating expenses:
Cost of revenue	1,866				2,312				7,974				7,704
Research and development	2,147				1,866				7,253				7,689
Selling, general and administrative	4,326				6,325				17,739				21,778
Amortization of intangible assets	939				937				3,758				3,748
Impairment of goodwill	—				360				—				360
Total operating expenses	9,278				11,800				36,724				41,279
Loss from operations	(7,372)				(10,299)				(29,482)				(35,294)
Other income (expense):
Interest income (expense), net	(350)				(418)				(1,550)				(2,006)
Loss before income taxes	(7,722)				(10,717)				(31,032)				(37,300)
Income tax provision (benefit)	(259)				(710)				(245)				(700)
Net loss and comprehensive loss	$	(7,463)			$	(10,007)			$	(30,787)			$	(36,600)
Deemed dividend applicable to beneficial conversion   feature of Series A preferred stock	(5,870)				—				(7,748) Werbung Mehr Nachrichten zur Roka Biosience Aktie kostenlos abonnieren E-Mail-Adresse Bitte überprüfe deine die E-Mail-Adresse. Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News 09:54 - PR Newswire BlackRock World Mining Trust Plc - Total Voting Rights 08:00 - PR Newswire Moonpig Group Plc - Holding(s) in Company 07:02 - PR Newswire Norges Bank - Form 8.3 - Darktrace plc Importverbot für Uran    Hammernachricht im Uran-Superzyklus weiterlesen» Anzeige wo-site-teaser-box-17145_site-teaser-box_2024-06-03_07%253A00%253A00_2024-06-04_09%253A00%253A59